Sera Prognostics, Inc.
Sera Prognostics, Inc. (SERA) Stock Overview
Explore Sera Prognostics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
SERA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Sera Prognostics, Inc. (SERA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $10.75.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.72 and a market capitalization of 150.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Evguenia Lindgardt
63
2749 East Parleys Way, Salt Lake City, UT
2021